{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:26:47Z","timestamp":1773908807183,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.humpath.2018.08.002","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T02:46:33Z","timestamp":1534387593000},"page":"206-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Concordance of somatic mutation profiles (BRAF, NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples"],"prefix":"10.1016","volume":"82","author":[{"given":"Shi","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick A.","family":"Leone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asok","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drazen","family":"Jukic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Sundram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Mahalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2018.08.002_bb0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2018.08.002_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/clpt.2013.197","article-title":"Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies","volume":"95","author":"Jang","year":"2014","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.humpath.2018.08.002_bb0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.08.002_bb0020","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.08.002_bb0025","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2018.08.002_bb0030","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.humpath.2018.08.002_bb0035","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.humpath.2018.08.002_bb0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/CMR.0000000000000048","article-title":"Melanomas of unknown primary frequently harbor TERT-promoter mutations","volume":"24","author":"Egberts","year":"2014","journal-title":"Melanoma Res"},{"key":"10.1016\/j.humpath.2018.08.002_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju246","article-title":"TERT promoter mutations as an independent prognostic factor in cutaneous melanoma","volume":"106","author":"Griewank","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2018.08.002_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00428-015-1784-x","article-title":"Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathologic features of aggressiveness","volume":"467","author":"Macerola","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2018.08.002_bb0055","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/pcmr.12441","article-title":"TERT promoter mutations associate with fast growing melanoma","volume":"29","author":"Nagore","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.humpath.2018.08.002_bb0060","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.humpath.2018.08.002_bb0065","first-page":"1","article-title":"Laser capture microdissection: insights into methods and applications","volume":"2018","author":"Mahalingam","year":"1723","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.humpath.2018.08.002_bb0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jmoldx.2015.07.010","article-title":"Varying mutational alterations in multiple primary melanomas","volume":"18","author":"Egberts","year":"2016","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2018.08.002_bb0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1479-5876-12-117","article-title":"Discrepant alterations in main candidate genes among multiple primary melanomas","volume":"12","author":"Colombino","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.humpath.2018.08.002_bb0080","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2018.08.002_bb0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.12771\/emj.2014.37.1.30","article-title":"Prevalence of BRAF and NRAS mutations and a comparative analysis in primary and metastatic melanoma of Korean patients","volume":"37","author":"Choi","year":"2014","journal-title":"Ewha Med J"},{"key":"10.1016\/j.humpath.2018.08.002_bb0090","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/bjc.2013.622","article-title":"Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations","volume":"109","author":"Heinzerling","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2018.08.002_bb0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1590\/S1676-24442010000600009","article-title":"BRAF mutations in cutaneous melanoma: no correlation with histological prognostic factors or overall survival","volume":"46","author":"Jung","year":"2010","journal-title":"J Bras Patol Med Lab"},{"key":"10.1016\/j.humpath.2018.08.002_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2018.08.002_bb0105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jdermsci.2013.07.013","article-title":"KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma","volume":"72","author":"Zebary","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.humpath.2018.08.002_bb0110","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2018.08.002_bb0115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1479-5876-11-202","article-title":"Heterogeneous distribution of BRAF\/NRAS mutations among Italian patients with advanced melanoma","volume":"11","author":"Colombino","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.humpath.2018.08.002_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070826","article-title":"Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing","volume":"8","author":"Boursault","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2018.08.002_bb0125","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.0022-202X.2005.23788.x","article-title":"BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival","volume":"125","author":"Akslen","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.humpath.2018.08.002_bb0130","first-page":"763","article-title":"Mutation stability in primary and metastatic melanoma: what we know and what we don't","volume":"30","author":"Varada","year":"2015","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.humpath.2018.08.002_bb0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment and decisions: a move towards precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2018.08.002_bb0140","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1038\/ncomms4401","article-title":"Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma","volume":"5","author":"Heidenreich","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2018.08.002_bb0145","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00432-016-2322-1","article-title":"Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients","volume":"143","author":"Ofner","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.humpath.2018.08.002_bb0150","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/CMR.0000000000000272","article-title":"Frequency of TERT promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases","volume":"26","author":"Yang","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.humpath.2018.08.002_bb0155","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/pcmr.12500","article-title":"High TERT promoter mutation frequency in non-acral cuatneous metastatic melanoma","volume":"29","author":"Ekedahl","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.humpath.2018.08.002_bb0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/bjc.2017.384","article-title":"Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma","volume":"118","author":"Hugdahl","year":"2018","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.humpath.2018.08.002_bb0165","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1158\/1078-0432.CCR-16-1821","article-title":"PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison","volume":"15","author":"Sunshine","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2018.08.002_bb0170","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2018.08.002_bb0175","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1073\/pnas.1607836113","article-title":"Association of PD-1\/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors","volume":"113","author":"Danilova","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2018.08.002_bb0180","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/modpathol.2016.210","article-title":"Tumoral PD-L1 expression in desmoplastic melanoma is associated with thickness of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant","volume":"30","author":"Frydenlund","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2018.08.002_bb0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.humpath.2017.06.012","article-title":"PD-L1 and immune escape\u2014insights from melanoma and other lineage-unrelated malignancies","volume":"66","author":"Frydenlund","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2018.08.002_bb9000","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2016"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771830306X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681771830306X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T10:34:55Z","timestamp":1545042895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681771830306X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":38,"alternative-id":["S004681771830306X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2018.08.002","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concordance of somatic mutation profiles (BRAF, NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2018.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}